Study guide

14.3 Encephalopathy, Delirium, and Acute Cognitive Change

AHIMA Certified Documentation Integrity Practitioner CDIP

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Authoritative Coding Resources & Conventions

1.1 Official Coding Resources: Scope, Authority & Research 1.2 General Coding Conventions, Punctuation & Instructional Notes 1.3 Chapter-Specific and Setting-Specific Coding Guidelines

2 Chapter 2: Principal & Secondary Diagnosis Determination

2.1 UHDDS Definitions & Principal Diagnosis Selection 2.2 Two or More Diagnoses Equally Meeting Criteria 2.3 Secondary Diagnosis Reporting Standards & POA Status

3 Chapter 3: Procedure Coding & Sequencing Standards

3.1 ICD-10-PCS Root Operations & Inpatient Procedure Coding 3.2 Principal Procedure Selection & Surgical Sequencing 3.3 Applying Official References to Ambiguous Records

4 Chapter 4: Inpatient Prospective Payment & DRG Grouping

4.1 MS-DRG Logic, CC/MCC Exclusions & Severity Levels 4.2 Working vs. Final DRG Assignment & Optimization vs. Maximization 4.3 CDI-Coding Reconciliation & Annual Regulatory Updates

5 Chapter 5: Enterprise CDI Promotion & Program Value

5.1 Articulating CDI Value to C-Suite & Hospital Leadership 5.2 Organizational Models, Inpatient/Outpatient Scope & Staffing 5.3 Cross-Functional Collaboration: HIM, Quality & Case Management

6 Chapter 6: Cross-Functional Alignment & Improvement Projects

6.1 Partnering with Nursing, Pharmacy & Allied Health Professionals 6.2 Documentation Improvement Project Identification & Scoping 6.3 Executing, Piloting & Measuring CDI Project Outcomes

7 Chapter 7: Physician Champion Engagement & Clinical Advocacy

7.1 Selection, Role & Credibility of the CDI Physician Champion 7.2 Peer-to-Peer Engagement, Coaching & Overcoming Resistance 7.3 Developing Standard CDI Operational Policies & Procedures

8 Chapter 8: Compliant Policy Architecture & Query Governance

8.1 AHIMA/ACDIS Practice Brief Standards in Policy Construction 8.2 Medical Record Integration of Provider Query Responses 8.3 Policies for Electronic, Paper, and Verbal Query Communications

9 Chapter 9: Query Escalation & Professional Communication

9.1 Chain of Command & Protocols for Unanswered Queries 9.2 Conflict Resolution & Professional Feedback Mechanisms 9.3 Assessing Stakeholder Learning Needs & Specialty Curricula

10 Chapter 10: Educational Delivery & Broader Healthcare Impacts

10.1 Delivery Methods: Microlearning, Case Studies & Grand Rounds 10.2 Documentation Impacts on Clinical Research & Epidemiology 10.3 Documentation Impacts on Case Management, LOS & Reimbursement

11 Chapter 11: Clinical Record Synthesis & Encounter Trajectory

11.1 Synthesizing Provider Notes, Consults & Progress Trajectory 11.2 Interpreting Diagnostic Imaging, Pathology & Labs 11.3 Resolving Conflicting, Ambiguous & Copy-Forward Entries

12 Chapter 12: Advanced Clinical Concepts & Review Prioritization

12.1 Pharmacotherapy, Clinical Trajectories & Disease Correlations 12.2 Inpatient Review Prioritization: High-Risk & High-Volume 12.3 Payer Prioritization, Length of Stay & Re-Review Cadence

13 Chapter 13: Clinical Indicator Mapping & Gap Recognition

13.1 Systematic Identification of Documentation Gaps 13.2 Sepsis Definitions, SEP-1, and Coding 13.3 AKI Criteria, Tubular Injury, and CKD Staging

14 Chapter 14: Diagnostic Precision in High-Impact Conditions

14.1 Respiratory Failure: Acuity, Evidence, and Sequencing 14.2 Heart Failure Phenotype, Acuity, and Hypertensive Combinations 14.3 Encephalopathy, Delirium, and Acute Cognitive Change

15 Chapter 15: Clinical Validation & Complication Discrepancies

15.1 Malnutrition Assessment, Severity, and Provider Documentation 15.2 Principles of a Compliant, Nonleading Query 15.3 Open-Ended, Multiple-Choice, and Yes/No Queries

16 Chapter 16: Query Mechanics & Direct Provider Collaboration

16.1 Electronic Query Systems, Templates, and Technology Oversight 16.2 Collaborating With the Appropriate Query Recipient 16.3 Capturing and Clarifying Query Responses

17 Chapter 17: Quality Indicators & Post-Discharge Clarification

17.1 Present on Admission Clarification and Selected HAC Rules 17.2 Clarifying Acuity, Cause, Site and Severity 17.3 Post-Discharge Query Opportunities and Limits 17.4 Managing Post-Discharge Query Workflows

18 Chapter 18: CDI Operational Dashboards & Quality Auditing

18.1 Departmental Metrics: Definitions, Calculations and Dashboard Use 18.2 Internal CDI Quality Audits and Reviewer Calibration 18.3 Query Trends: Understanding the Process and Provider Experience

19 Chapter 19: Benchmarking, Productivity & Data-Driven Workflow

19.1 Provider Documentation Benchmarking 19.2 External Benchmarking: CMI, Severity, Mortality and Length of Stay 19.3 Evaluating CDI Professional Performance 19.4 Using Data to Design CDI Workflow and Staffing

20 Chapter 20: Ethical CDI Standards & Regulatory Frameworks

20.1 Applying AHIMA Ethics to CDI Decisions 20.2 Responding to Financial Pressure and Upcoding Risks 20.3 Maintaining Competence and Professional Integrity

21 Chapter 21: Regulatory Compliance & Enforcement Landscapes

21.1 False Claims, Overpayments and Referral Laws 21.2 Regulatory Agencies, Review Contractors and Appeals 21.3 EHR Templates, Copied Text and Record Integrity

22 Chapter 22: Technology Risks & Second-Level Review Protocols

22.1 CAC, NLP and AI: Context, Oversight and Performance 22.2 Selecting Cases for Second-Level Review 22.3 Conducting and Closing a Second-Level Review

23 Chapter 23: Clinical Validation Queries & Risk Mitigation

23.1 Clinical Validation and Coding Clarification 23.2 Clinical Validation Queries and Denial Evidence 23.3 Detecting Leading, Biased and Unsupported Queries

24 Chapter 24: Noncompliant Query Remediation & Query Lifecycle Management

24.1 Query Remediation and Corrective Action 24.2 Query Timeframes, Aging and Measurement 24.3 Query Records, Retention and Evidence Preservation

14.3 Encephalopathy, Delirium, and Acute Cognitive Change

Key Takeaways Explain This Topic AI

The 2020 ten-society statement describes acute encephalopathy as a pathobiological process that can present as delirium or coma; delirium is not a clinically lesser psychiatric substitute.

Baseline, serial findings, causes, management and trajectory inform review. No universal score, laboratory threshold, treatment, or return-to-baseline requirement independently establishes every encephalopathy.

The FY 2027 Index distinguishes metabolic G93.41, unspecified toxic G92.9, and toxic metabolic G92.8; follow applicable drug-event instructions and actual provider documentation.

Hepatic encephalopathy NOS or without coma indexes to K76.82 with underlying-liver-disease and exclusion instructions. Do not infer coma or liver failure from confusion or treatment.

Final v44 lists F05 and G93.40 as CCs, and G93.41/G92.8/G92.9 as MCCs when secondary, subject to exclusions. Severity classification does not select the clinical diagnosis.

Last updated: October 2026

Acute cognitive change: establish the syndrome and its cause

A sudden change in attention, awareness, cognition, or responsiveness deserves an explanation in the clinical record. CDI must distinguish what observers recorded, what syndrome the clinician established, and what cause is documented. “Confused,” a Glasgow Coma Scale result, a positive delirium assessment, and a diagnosis of metabolic encephalopathy are different kinds of information. One should not be silently substituted for another.

Begin with the patient's baseline and the time course. Family reports, prior relevant records, nursing observations, examination, medication history, and serial assessments can help explain what changed. Preserve their sources and limitations. An existing dementia diagnosis does not automatically explain a new acute deterioration, but an acute illness in a patient with dementia does not automatically establish metabolic encephalopathy either.

Delirium and encephalopathy describe related concepts

The 2020 consensus endorsed by ten professional societies recommends acute encephalopathy for a rapidly developing pathobiological brain process, usually over hours or days and within a period shorter than four weeks. It can present clinically as subsyndromal delirium, delirium, or coma. The statement recommends using the appropriate clinical term for the observed presentation rather than using encephalopathy as a description of bedside findings alone.

Delirium concerns an acute and fluctuating disturbance in attention and awareness with additional cognitive change, evaluated in relation to baseline and the clinical context. It is not merely a psychiatric label for a clinically unimportant problem. The consensus warns that separating the terminology into unrelated disease hierarchies can impede understanding and care.

Coma concerns profoundly depressed responsiveness; it is not interchangeable with ordinary inattention or delirium. Dementia concerns an established neurocognitive disorder whose baseline course and functional effects must be distinguished from a superimposed acute syndrome. A quiet or hypoactive presentation can still warrant assessment; review actual findings instead of looking only for agitation.

These clinical distinctions do not independently authorize a particular ICD-10-CM code set. Do not treat a nomenclature statement as a coding instruction to report every related term separately, or to replace a documented delirium diagnosis with an encephalopathy code. Review the actual diagnoses, classification instructions, reportability, and any unresolved ambiguity.

Build an evidence timeline

Review question Useful evidence Inference to avoid

What was the baseline? Established cognition, communication, activities, and usual responsiveness Assuming all current impairment is dementia because dementia is on the problem list

What changed and when? Dated observations, family description, attention/awareness assessment, fluctuation Calling any isolated confusion an established acute metabolic disorder

What explanations were considered? Provider differential, examination, relevant testing, exposures Selecting a cause from one abnormal laboratory value

What was actually done? Evaluation, administered treatment, medication changes, monitoring, safety measures Treating a medication order as proof of a particular encephalopathy

What was the subsequent course? Improvement, persistence, fluctuation, new information, provider reassessment Requiring return to baseline before the diagnosis can be valid

GCS and delirium instruments help describe or assess particular clinical features; neither supplies a universal numerical threshold for every encephalopathy. A positive CAM assessment does not independently establish a metabolic or toxic etiology. A documented GCS may be available under its coding documentation exception, but that exception does not permit the coder to diagnose encephalopathy from the score.

Consider causes without converting them into diagnoses

Metabolic illness, systemic infection, medication or toxin effects, and liver disease can be relevant clinical contexts. Multiple factors may coexist. Review the provider's interpretation of each factor and the alternative explanations rather than making a one-to-one rule from a laboratory threshold to a brain diagnosis.

For example, a creatinine rise with cognitive change warrants clinical assessment; it does not independently establish uremic or metabolic encephalopathy. Similarly, the mere presence of infection does not determine that all cognitive changes are septic encephalopathy. The clinician may identify a different cause, several causes, or unresolved uncertainty.

Medication review should distinguish exposure, prescribed use, administration, suspected adverse effect, overdose, and withdrawal. Sedation around a procedure and a drug-induced pathologic condition are not interchangeable. Document the implicated drug and relationship when established, and apply the relevant drug-event instructions rather than inferring poisoning from somnolence or a reversal-agent order.

The causal assessment can also change over the admission. An early provisional explanation may be ruled out or refined. Resolve meaningful conflicts rather than retaining every earlier possibility as a final diagnosis. Persistent impairment does not automatically invalidate an acute process, and improvement after treatment does not alone prove which process caused it.

Hepatic encephalopathy is a clinical assessment

Liver dysfunction and portosystemic shunting can contribute to hepatic encephalopathy. The AASLD's 2025 educational discussion emphasizes that ammonia results do not consistently track the severity of hepatic encephalopathy and that altered mental status in cirrhosis cannot always be attributed to it. Sample handling and processing can also affect ammonia measurements.

Thus, an elevated ammonia value is not a universal diagnostic or staging cutoff for HE. Preserve the examination, clinical course, precipitating factors, competing explanations, and specialist assessment. Treatment such as lactulose or rifaximin can support the clinical timeline but does not independently establish the diagnosis, coma, or liver failure.

The AASLD's currently posted dedicated chronic-liver-disease guideline is dated 2014; do not present it as a new 2026 definition or apply its chronic-liver population indiscriminately to acute liver failure. For this documentation task, the supported principle is that the clinician assesses the syndrome in its liver-disease context rather than CDI assigning it from ammonia or treatment alone.

Verify exact FY 2027 terms and instructions

  • Documented term or distinction FY 2027 classification point
  • Encephalopathy, unspecified G93.40; do not invent a metabolic cause to avoid an unspecified diagnosis
  • Metabolic encephalopathy G93.41, including septic encephalopathy
  • Unspecified toxic encephalopathy G92.9
  • Toxic metabolic encephalopathy G92.8, other toxic encephalopathy; it is not interchangeable with G93.41

Hepatic encephalopathy NOS or without coma Index directs K76.82; review its code-also and exclusion instructions

Delirium due to a known physiological condition F05, with a code-first instruction for the underlying physiological condition

Altered mental status, unspecified R41.82, a symptom description rather than automatic proof of one of the above diagnoses

G92.8 and G92.9 include instructions concerning poisoning and adverse effects when applicable: poisoning is coded first under the specified instructions, while an applicable adverse-effect code identifies the drug additionally. A medication history alone does not establish that a drug event occurred.

K76.82 directs coding also the underlying liver disease, such as specified hepatic failure or viral hepatitis when documented. Its exclusions address hepatic failure with coma. Do not infer coma from confusion, or hepatic failure merely from a diagnosis of hepatic encephalopathy. K72.90 means hepatic failure, unspecified, without coma; it does not mean chronic hepatic failure without coma, which is K72.10. Follow the full documented condition and applicable instructions rather than mapping every HE case to K72.-.

F05 includes delirium superimposed on dementia and has its own code-first instruction. Delirium NOS follows a different Index/Tabular path; not every use of the word “delirium” automatically establishes F05 or its underlying condition. Substance-related disorders also have specific classification pathways. Check the complete term and circumstances.

Clinical significance is not a severity-code hierarchy

Final MS-DRG v44 Appendix C lists F05 and G93.40 as CCs , while G93.41, G92.8, and G92.9 are MCCs when secondary, subject to exclusions and complete grouping. K76.82 is not listed as a CC/MCC in Appendix C part 1. F01.511, vascular dementia of unspecified severity with agitation, is a CC; an entire dementia code range must not be labeled non-CC. These facts cannot be generalized to all encephalopathies, all dementia codes, all DRGs, or other risk models.

An MCC designation does not make one diagnostic term clinically preferable, establish that it exists, or guarantee a different payment. A CC or symptom diagnosis can be accurate and clinically important. Do not request a metabolic or toxic label simply to replace delirium or an unspecified diagnosis with a higher severity category.

Ask the question the record actually leaves open

Suppose a patient with a stable documented dementia baseline develops a substantial new attention and responsiveness change during an acute illness. The final notes still say only “confusion.” A justified clarification can present the baseline, dated changes, relevant results, actual interventions, and the provider's existing assessments, then ask about the acute condition and cause, if known. Permit clinically supported alternatives and an inability to determine the answer. Do not announce that a sodium or BUN threshold has already substantiated an MCC.

If an involved consultant has already documented a compatible specific diagnosis, check whether a genuine unresolved question remains; do not demand duplicate attending wording solely as a routine rule. A true diagnostic conflict requires resolution through the appropriate process. Ensure the response meets permanent-record requirements and apply reportability and sequencing separately.

For a clinical-validation concern, ask for the provider's rationale or clarification using relevant supporting and contrary evidence. Baseline, neurological findings, possible causes, management, and trajectory are useful review dimensions. They are not four mandatory pillars guaranteeing a successful appeal, nor a rule requiring a specific drug, biomarker cutoff, or recovery before discharge.

Sources: 2020 ten-society nomenclature consensus ; AASLD 2025 ammonia and encephalopathy discussion ; AASLD dedicated guideline page and date ; FY 2027 ICD-10-CM guidelines, I.A.19, I.B.14 and III ; FY 2027 Index and Tabular List ; final MS-DRG v44 Appendix C ; 2026 query brief .